Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, Thierry Facon
{"title":"皮下达拉单抗联合卡非佐米和地塞米松(D-Kd)与卡非佐米和地塞米松(Kd)治疗复发/难治性多发性骨髓瘤患者:LYNX研究","authors":"Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, Thierry Facon","doi":"10.1080/10428194.2025.2561117","DOIUrl":null,"url":null,"abstract":"<p><p>Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1-3 prior lines of therapy, one of which contained daratumumab, were randomized to receive subcutaneous daratumumab plus carfilzomib/dexamethasone (D-Kd; <i>n</i> = 44) or carfilzomib/dexamethasone (Kd; <i>n</i> = 44). The primary endpoint was the very good partial response or better (≥VGPR) rate. At the interim futility analysis, no significant differences in ≥ VGPR rates were found between treatment groups; therefore, the null hypothesis of no treatment difference was accepted, leading to study termination. At the final analysis, 45.5% of D-Kd patients and 40.9% of Kd patients achieved ≥ VGPR (odds ratio, 1.2 [90% CI, 0.59-2.46]; <i>p</i> = 0.6757). No new safety concerns were identified. Future studies are needed to optimize daratumumab-based regimens for patients with RRMM who have prior daratumumab exposure.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.2000,"publicationDate":"2025-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.\",\"authors\":\"Nizar J Bahlis, Jeffrey Zonder, Lionel Karlin, Torben Plesner, Laura Paris, Tomasz Wrobel, Vania Hungria, Britta Besemer, Edvan Crusoe, Trine Silkjaer, Aurore Perrot, Philippe Moreau, Ka Lung Wu, Sosana Delimpasi, Meletios A Dimopoulos, Mark-David Levin, Silvia Mangiacavalli, Ivo Nnane, Yu Jin Kim, Maria Krevvata, Linlin Sha, Susan Wroblewski, Alba Tuozzo, Robin Carson, Thierry Facon\",\"doi\":\"10.1080/10428194.2025.2561117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1-3 prior lines of therapy, one of which contained daratumumab, were randomized to receive subcutaneous daratumumab plus carfilzomib/dexamethasone (D-Kd; <i>n</i> = 44) or carfilzomib/dexamethasone (Kd; <i>n</i> = 44). The primary endpoint was the very good partial response or better (≥VGPR) rate. At the interim futility analysis, no significant differences in ≥ VGPR rates were found between treatment groups; therefore, the null hypothesis of no treatment difference was accepted, leading to study termination. At the final analysis, 45.5% of D-Kd patients and 40.9% of Kd patients achieved ≥ VGPR (odds ratio, 1.2 [90% CI, 0.59-2.46]; <i>p</i> = 0.6757). No new safety concerns were identified. Future studies are needed to optimize daratumumab-based regimens for patients with RRMM who have prior daratumumab exposure.</p>\",\"PeriodicalId\":18047,\"journal\":{\"name\":\"Leukemia & Lymphoma\",\"volume\":\" \",\"pages\":\"1-12\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-10-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Leukemia & Lymphoma\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1080/10428194.2025.2561117\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Leukemia & Lymphoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/10428194.2025.2561117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0
摘要
基于daratumumab的方案在复发/难治性多发性骨髓瘤(RRMM)中显示出临床疗效。随着越来越多的患者接受以达拉图单抗为基础的一线治疗,需要评估达拉图单抗再治疗。在2期LYNX研究(ClinicalTrials.gov Identifier: NCT03871829)中,88名RRMM患者接受了1-3个先前的治疗,其中一个含有达拉单抗,随机接受皮下达拉单抗加卡非佐米/地塞米松(D-Kd; n = 44)或卡非佐米/地塞米松(Kd; n = 44)。主要终点是非常好的部分缓解或更好的(≥VGPR)率。在中期无效分析中,治疗组间≥VGPR率无显著差异;因此,无治疗差异的原假设被接受,导致研究终止。在最终分析中,45.5%的D-Kd患者和40.9%的Kd患者达到≥VGPR(优势比为1.2 [90% CI, 0.59-2.46]; p = 0.6757)。没有发现新的安全隐患。未来的研究需要优化先前有达拉图单抗暴露的RRMM患者的基于达拉图单抗的方案。
Subcutaneous daratumumab plus carfilzomib and dexamethasone (D-Kd) versus carfilzomib and dexamethasone (Kd) in patients with relapsed/refractory multiple myeloma who received previous daratumumab treatment: LYNX study.
Daratumumab-based regimens demonstrate clinical efficacy in relapsed/refractory multiple myeloma (RRMM). As more patients receive frontline daratumumab-based therapy, evaluation of daratumumab retreatment is needed. In the phase 2 LYNX study (ClinicalTrials.gov Identifier: NCT03871829), 88 patients with RRMM who received 1-3 prior lines of therapy, one of which contained daratumumab, were randomized to receive subcutaneous daratumumab plus carfilzomib/dexamethasone (D-Kd; n = 44) or carfilzomib/dexamethasone (Kd; n = 44). The primary endpoint was the very good partial response or better (≥VGPR) rate. At the interim futility analysis, no significant differences in ≥ VGPR rates were found between treatment groups; therefore, the null hypothesis of no treatment difference was accepted, leading to study termination. At the final analysis, 45.5% of D-Kd patients and 40.9% of Kd patients achieved ≥ VGPR (odds ratio, 1.2 [90% CI, 0.59-2.46]; p = 0.6757). No new safety concerns were identified. Future studies are needed to optimize daratumumab-based regimens for patients with RRMM who have prior daratumumab exposure.
期刊介绍:
Leukemia & Lymphoma in its fourth decade continues to provide an international forum for publication of high quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies. The scope ranges from clinical and clinico-pathological investigations to fundamental research in disease biology, mechanisms of action of novel agents, development of combination chemotherapy, pharmacology and pharmacogenomics as well as ethics and epidemiology. Submissions of unique clinical observations or confirmatory studies are considered and published as Letters to the Editor